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ApoptosisMitochondria are signal-integrating organelles involved in cell death induction. Mitochondrial alterations and
reduction in energy metabolism have been previously reported in the context of glucocorticoid (GC)-
triggered apoptosis, although themechanism is not yet clariﬁed.We analyzedmitochondrial function in a GC-
sensitive precursor B-cell acute lymphoblastic leukemia (ALL) model as well as in GC-sensitive and GC-
resistant T-ALL model systems. Respiratory activity was preserved in intact GC-sensitive cells up to 24 h under
treatment with 100 nM dexamethasone before depression of mitochondrial respiration occurred. Severe
repression of mitochondrial respiratory function was observed after permeabilization of the cell membrane
and provision of exogenous substrates. Several mitochondrial metabolite and protein transporters and two
subunits of the ATP synthase were downregulated in the T-ALL and in the precursor B-ALL model at the gene
expression level under dexamethasone treatment. These data could partly be conﬁrmed in ALL lymphoblasts
from patients, dependent on the molecular abnormality in the ALL cells. GC-resistant cell lines did not show
any of these defects after dexamethasone treatment. In conclusion, in GC-sensitive ALL cells, dexamethasone
induces changes in membrane properties that together with the reduced expression of mitochondrial
transporters of substrates and proteins may lead to repressed mitochondrial respiratory activity and lower
ATP levels that contribute to GC-induced apoptosis. This article is part of a Special Issue entitled: Bioenergetics
of Cancer.ergetics of Cancer.
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Mitochondria are involved in many vital metabolic pathways, e.g.
citric acid cycle (TCA), energy transformation, amino acidmetabolism,
and urea cycle. This is reﬂected in their complex architecture and the
high number of metabolite transport systems [1,2] tightly controlled
by membrane potential (electrogenic substrate transport), proton
gradients (protonogenic substrate transport), and substrate gradients,
including the gradient of inorganic phosphate, Pi. Although mito-
chondria possess their own genome, they mainly depend on import of
proteins, synthesized by cytoplasmic ribosomes and imported via
mitochondrial protein translocases. Translocases of the outer mito-
chondrial membrane (TOMM) and inner mitochondrial membrane
(TIMM) facilitate protein uptake and insertion. A disturbed transport
of newly synthesized proteins into mitochondria can impair growth,cell proliferation, and respiration of affected cells [3]. Mitochondria
are important death signal integrators and key organelles involved in
the onset of the intrinsic apoptotic pathway [4,5]. Membrane
alterations, reduction of mitochondrial membrane potential, and
release of pro-apoptotic proteins, such as cytochrome c and apoptosis
inducing factor (AIF), are well described events of this apoptotic
pathway, induced by a variety of cell death stimuli. Because of their
ability to induce cell cycle arrest and cell death, glucocorticoids (GC)
are exploited in the therapy of lymphoid malignancies, particularly in
childhood acute lymphoblastic leukemia (ALL) [6,7]. Despite a high
cure rate (75%), severe therapy related side effects, resistance
development, and relapses are frequently observed.
Besides proteins of the Bcl-2 family, metabolic alterations are
involved in GC-induced apoptosis [8]. Reduction in cellular glucose
uptake, lactate production, and ATP content have been described
recently [9,10]. Conversely, upregulation of important metabolic
pathways including glycolysis, oxidative phosphorylation, glutamate
metabolism, and cholesterol biosynthesis at the transcriptional level
have been related to GC resistance [11]. Nevertheless, the complex
pattern of GC-induced mitochondrial alterations and their involvement
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therapy protocols and revert GC resistance.
In a previous study, we investigated the time response of respiratory
activity under treatment with dexamethasone (DEX) in intact cells and
showed preserved ROUTINE respiration and capacity of the electron
transport system (ETS) up to 24 h of treatment but a signiﬁcant
reduction after 36 h [9]. To gain more insight into GC-induced
mitochondrial alterations, we measured mitochondrial respiratory
activity in detail in GC-sensitive and resistant cell lines by high-
resolution respirometry. Mitochondrial respiratory capacity was ana-
lyzed after cellmembrane permeabilizationwith digitonin and addition
of substrates feeding electrons into complex I (CI) and complex II (CII)
separately or simultaneously. DEX treatment resulted in repressed
mitochondrial activity in GC-sensitive but not in GC-resistant cells.
Furthermore,we frequently detected cytochrome c release in onemodel
system. These results together with the ﬁnding that a variety of
mitochondrial transporters involved in metabolite transport and
protein uptakewere downregulated at themRNA level indicate changes
in mitochondrial membrane properties in the course of GC-induced cell
death in ALL.
2. Materials and methods
2.1. Cell culture
The GC-sensitive cell lines CCRF-CEM-C7H2 [12], NALM-6 (ACC
128, DSMZ), and 697/EU-3 ALL [13], and the GC-resistant cell lines
CEM-C7H2-R9C10 and CEM-C7H2-R1C57 [14] were used as ALL
model systems. The original name of the cell line 697/EU-3 given by
its generator was “line 697,” but it was renamed recently EU-3 [15].
Cells were maintained in RPMI 1640 supplemented with 10% heat-
inactivated tetracycline-free fetal calf serum, 2 mM L-glutamine (all
PAA; Pasching, Austria) in a humidiﬁed atmosphere of 95% air and 5%
CO2 at 37 °C. All cell lines were regularly tested for mycoplasma
contamination (Minerva Biolabs, Berlin, Germany) and were found to
be negative.
2.2. Induction and determination of apoptosis
Cells were diluted to 3×105 cells/mL and incubated with 100 nM
DEX (Sigma-Aldrich, St. Louis, MO, USA). Control cells were treated
with carrier only, i.e. 0.1% (vol./vol.) ethanol. Apoptosis was
determined by ﬂow cytometric analysis (Beckman Coulter, Krefeld,
Germany) of the sub-G1 fraction after DNA staining according to
Nicoletti [16].
2.3. Cell number and protein determination
Cell numbers and volumes were analyzed by means of a CASY1 TT
cell counter (Schärfe System, Reutlingen, Germany). Protein content
was measured in the presence of a protease inhibitor (Pierce,
Rockford, IL, USA) using the Coomassie Plus Protein Assay Reagent
Kit (Pierce) with bovine serum albumin as standard.
2.4. ATP quantiﬁcation
Intracellular ATP levels were measured in freshly harvested cells
by a luminescence assay (Promega, Madison, WI, USA). The emitted
light was proportional to the ATP concentration. An ATP standard
curve was generated to quantify cellular ATP according to the
manufacturer's protocol.
2.5. Cell fractionation
Approximately 6×107 cells were harvested, washed with cold PBS
3 times, resuspended in 1 mL mitochondria isolation buffer (10 mMHEPES, pH 7.4, 0.25 M sucrose, 1 mM EDTA, 0.1 mM phenylmethyl-
sulfonylﬂuoride, 1 mM sodium ﬂuoride, 0.2 mM sodium vanadate),
and centrifuged at 500g for 2 min at 4 °C. The supernatant was
discarded and the pellet was resuspended in 1 mL of isolation buffer.
The cells were mechanically disrupted by 20 strokes in a glass/Teﬂon
potter and fractions were separated by differential centrifugation
(500g for 2 min, 1,500g for 10 min, 12,000g for 10 min, all at 4 °C) to
obtain the mitochondria-enriched fraction.
2.6. High-resolution respirometry
Activity of the respiratory system was analyzed in a two-channel
titration injection respirometer (Oxygraph-2k; Oroboros Instruments,
Innsbruck, Austria) at 37 °C. Cells were harvested, resuspended in
mitochondrial medium MiR05 [17], and transferred to the oxygraph
chambers at ﬁnal cell densities of approximately 1×106 cells per
milliliter. In the ﬁrst substrate-uncoupler-inhibitor titration (SUIT)
protocol (Fig. 1A and B), ROUTINE respiration (no additions),
LEAK respiration (oligomycin-inhibited, 2 μg/mL), and ETS capacity
(maximum non-coupled respiration induced by stepwise (typically
2–3 steps) titration of carbonyl cyanide p-(triﬂuoromethoxy) phe-
nylhydrazone (FCCP; 2 μM solved in ethanol)) were measured in
intact cells respiring on endogenous substrates. Subsequently, the
plasma membrane was permeabilized with digitonin (8.1 μM), and
CI-dependent ETS capacity (CIETS) was stimulated by glutamate
(G; 10 mM) and malate (M; 2 mM) addition (5 mM pyruvate did
not result in a further increase in respiration, data not shown). After
addition of succinate (S; 10 mM), ETS capacity was obtained with
convergent CI+II electron ﬂow into the Q-junction (ETSCI+ II) [18].
Subsequent addition of rotenone (Rot; 0.5 μM) allowed the determi-
nation of CII supported ETS capacity (CIIETS). Residual oxygen
consumption (ROX) was evaluated after inhibition of CIII with
antimycin A (Ama; 2.5 μM). In a second SUIT protocol (Fig. 1C and
D), after determination of ROUTINE respiration, the plasma mem-
brane was permeabilized with digitonin and the capacity of oxidative
phosphorylation (OXPHOS) with CI-related substrates (G+M) was
determined after stimulation by ADP (D; 2.5 mM; CIOXPHOS), followed
by addition of S (CI+IIOXPHOS). In the next step, ETS capacity was
measured by uncoupling with FCCP (CI+IIETS). Finally, CIIETS and ROX
were determined as in the ﬁrst protocol. Integrity of the outer
mitochondrial membrane was checked by the addition of cytochrome
c (10 μM) to CI respiration in both protocols. The absence of a
stimulatory effect of cytochrome c on respiration was used as a
positive test for integrity of the outer mitochondrial membrane [19].
For further details on SUIT protocols, see reference 20.
2.7. Immunoblotting
Proteins of the mitochondria-enriched fractions were size-frac-
tionated by SDS–PAGE, blotted on PVDF membranes (Millipore,
Billerica, MA, USA), blocked with 5% skimmilk in 10 mM Tris Buffered
Saline Tween 20 (TBST) buffer, and incubated with rabbit polyclonal
anti-TOMM40 (Santa Cruz Biotechnology, Santa Cruz, CA, USA;
diluted 1:500 in 5% skim milk in TBST), mouse monoclonal anti-
TIMM8A (Abcam, Cambridge, UK; diluted 1:1000 in 5% skim milk in
TBST), and rabbit monoclonal anti-COXIV (Cell Signaling Technology,
Danvers, MA, USA; diluted 1:1000 in 5% skimmilk in TBST) antibodies.
Horseradish peroxidase conjugated secondary antibodies (GE Health-
care, Buckinghamshire, UK; diluted 1:2500 in 5% skim milk in TBST)
were visualized by an enhanced chemiluminescence reagent (ECL
Plus, Amersham, Uppsala, Sweden) and detected by the Molecular
Imager® VersaDoc™ MP 4000 system (Bio-Rad Laboratories Inc.,
Hercules, CA, USA). Single bands were analyzed densitometrically
using the Quantity One Software (Bio-Rad Laboratories). TIMM8A and
TOMM40 bands were normalized against the mitochondrial loading
control COXIV.
Fig. 1. Online high-resolution respirometry traces of mitochondrial respiration in representative experiments with two protocols applied to control (A,C) and DEX-treated (B,D)
C7H2 cells after 24 h of incubation. Titrations (A and B): ROUTINE respiration (intact cells in MiR05), oligomycin (Omy; LEAK respiration), FCCP (2 steps; ETS capacity), digitonin
(Dig), glutamate+malate (GM; CIETS), cytochrome c (Cyt c), succinate (S; CI+IIETS), rotenone (Rot; CIIETS), antimycin A (Ama; ROX). In A and B, respiration was uncoupled with
FCCP in intact cells and, subsequently, the cell membrane was permeabilized. Titrations (C and D): ROUTINE respiration, Dig, G, M, and ADP (CIOXPHOS), Cyt c, S (CI+IIOXPHOS), FCCP
titration (CI+IIETS), Rot (CIIETS), Ama (ROX). Vertical lines indicate titrations. Respiration was reduced in permeabilized cells in both protocols.
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Generation of the Affymetrix Exon microarray (HuEx-1.0-st v2)
data sets have been published ([21] and Rainer et al., in preparation).
In brief, total RNA from GC-sensitive ALL cell lines CCRF-CEM-C7H2,
697/EU-3, and NALM-6, which had been cultured in the presence and
absence of 100 nM DEX, respectively, were hybridized to Exon
microarrays using standard protocols. Raw microarray data were
preprocessed using the GCRMA algorithm [22]. P-values for signiﬁ-
cance of differential expression were calculated using the moderated
t-test [23] and adjusted for multiple hypothesis testing using the
method by Benjamini and Hochberg [24].
The characteristics of 27 childhood ALL patients (7 T-ALL and 20
precursor B-ALL patients) and the generation of their gene expression
proﬁles during systemic GC monotherapy has been described
previously ([25] and Rainer et al., in preparation). In brief, total RNA
was extracted from Ficoll-puriﬁed and MACS-sorted (if blast counts
were below 80%) peripheral lymphoblasts of childhood ALL patients
prior to and 24 h after initiation of GC therapy following the BFM
(Berlin–Frankfurt–Münster) therapy protocol recommendations, con-
verted into labeled targets, and hybridized to Affymetrix HGU133 Plus
2.0 GeneChips according to the manufacturer's standard protocols.
Microarrays were preprocessed using the GCRMA method.
3. Results
3.1. Determination of apoptosis and protein content under GC treatment
Cells were treated with 100 nM DEX, a concentration chosen with
regard to its clinical relevance. After 24 h of DEX treatment, the
apoptotic rates of both the CCRF-CEM-C7H2 and the 697/EU-3 cell line
were comparable to controls (7%±2%) as measured by sub-G1 peak
detection. Cell death kinetics differed between the two cell lines.
About 27%±5% of the C7H2 cells were apoptotic after 36 h, whereasin the case of 697/EU-3, apoptotic cells were ﬁrst detected after 48 h
(13%±4%). In CEM-CCRF-C7H2 cells also, protein content changed
signiﬁcantly after 24 h (control, 0.144±0.009 mg/106 cells; DEX,
0.118±0.008 mg/106 cells*, Pb0.05) and after 36 h (control, 0.125±
0.009; DEX, 0.089±0.008 mg/106 cells*, Pb0.05) of treatment. In
697/EU-3 cells, protein content was slightly decreased after 24 h
(control, 0.098±0.008 mg/106 cells; DEX, 0.082±0.005 mg/106
cells) and was unchanged after 36 h (control, 0.097±0.01 mg/106
cells; DEX, 0.105±0.011 mg/106 cells) of treatment. All respiratory
data in this study were already corrected for alterations in cell size.
3.2. Mitochondrial respiratory capacity
We analyzed mitochondrial respiratory capacity in two GC-
sensitive model systems for acute lymphoblastic childhood leukemia,
the CCRF-CEM-C7H2 cell line as a T-ALL and the 697/EU-3 cell line as a
precursor B-ALL model, and two GC-resistant cell lines, the CEM-
C7H2-R9C10 and CEM-C7H2-R1C57 cells. Since we were interested in
events prior to cell death, we investigated mitochondrial function in
detail already after 24 h of treatment with carrier only or 100 nMDEX.
We applied two different respirometric protocols (see section 2.6),
adapted from Gnaiger [18], to gain insight into mitochondrial
respiratory function. We found a remarkable difference between the
two model systems in their characteristics of the respiratory systems
in controls.Whereas ROUTINE respirationwas quite similar in the two
model systems (Table 1), ETS and OXPHOS capacity was signiﬁcantly
lower in the B-ALL cells (Fig. 2). CI+II supported respiration was
highly sensitive to uncoupling, as seen by the increase in ETS capacity
versus OXPHOS capacity in the presence of the GMS substrate combi-
nation (Fig. 2), showing a substantial limitation by the phosphory-
lation system.
The DEX effect was comparable for the two GC-sensitive cell lines,
although it was more pronounced in the T-ALL model. After 24 h of
incubation, ROUTINE respiration and non-coupled ETS capacity on
Table 1
Mitochondrial ROUTINE respiration and ETS capacity in intact cells and ATP levels after
24 and 36 h of treatment with carrier (0.1% ethanol; C) and 100 nM dexamethasone
(DEX), respectively, in C7H2 T-ALL cells and 697/EU-3 preB-ALL cells.
ROUTINE ETS ATP
[pmol s−1 mg−1] [pmol s−1 mg−1] [nmol mg−1]
C7H2
24 h C 216±6 468±35 43±0
DEX 211±4 466±36 42±1
36 h C 214±5 534±5 49±1
DEX 157±5⁎⁎⁎ 369±29⁎ 41±1⁎⁎
697/EU-3
24 h C 187±6 305±13 39±2
DEX 171±15 219±46 40±2
36 h C 189±9 327±42 42±6
DEX 117±12⁎⁎⁎ 171±52 28±3⁎
ROUTINE respiratory activity at physiological levels of coupling and ETS capacity in the
non-coupled state were measured in intact cells by high-resolution respirometry and
related to cellular protein content. ATP concentrations [ATP] were measured in viable
cells. Arithmetic means±SEM and statistical signiﬁcance compared to controls. N=7.
⁎ Pb0.05.
⁎⁎ Pb0.01.
⁎⁎⁎ Pb0.001.
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and DEX-treated cells (Table 1). Coupling was not signiﬁcantly
altered, as indicated by the preserved LEAK/ETS control ratioA
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Fig. 2. Reduction of respiration after 24 h of treatment with 100 nM DEX in
permeabilized CEM-CCRF-C7H2 (A) and 697/EU-3 cells (B), respectively, respiring on
exogenous substrates. Respiratory states are CIOXPHOS: 10 mM glutamate+2 mM
malate (GM) and 2.5 mM ADP (D). CIETS: GM, non-coupled state with FCCP. CIIETS:
10 mM succinate (S), inhibition of CI by rotenone (0.5 μM), non-coupled state with
FCCP. CI+IIOXPHOS: GMS+D. ETSCI+ II: GMS+FCCP. Arithmetic means±SEM and
statistical signiﬁcance compared to controls (*Pb0.05, **Pb0.01, ***Pb0.001); N=5.(oligomycin-inhibited relative to non-coupled respiration) shown
previously [9]. Subsequent permeabilization of the plasma membrane
and addition of CI- and CII-related substrates resulted in reduced
oxygen consumption under DEX treatment (Fig. 1B). In both models,
CIETS and CIIETS were reduced, as well as ETS capacity supported by
CI- and CII-related substrates simultaneously (Fig. 2). Convergent
electron input in the ETS increased respiration in control cells
compared to separate supply of CI- or CII-substrates. Treatment with
DEX not only abolished the stimulatory effect of the addition of
succinate to CI substrate-supported respiration (Fig. 1B and D, Fig. 2A
and B) but also decreased respiratory activity in some experiments.
The lack of stimulation by providing CI and CII-substrates simulta-
neously cannot be explained by a complete loss of CII function because
there was still respiratory activity after rotenone addition (Fig. 2).
A reduction in OXPHOS was detected in both model systems but
was statistically signiﬁcant only in the CEM-CCRF-C7H2 cell line. 697/
EU-3 cells were very sensitive to lowering the membrane potential by
uncoupling with FCCP prior to permeabilization. The effects on
respiratory parameters were much more pronounced in the non-
coupled state.
In experiments with DEX-treated CEM-CCRF-C7H2 cells, we fre-
quently detected a decline in respiration over time after digitonin
permeabilization of the plasmamembrane. The addition of cytochrome
c stabilized and increased CI respiration, as shown in Fig. 1B and D. This
effect was not observed in 697/EU-3 (data not shown). Since in intact
cells, ROUTINE respiration and ETS capacity were unchanged after 24 h
of DEX treatment compared to control cells, we concluded that
cytochrome c release was induced after cell membrane permeabiliza-
tion. After 36 h of DEX treatment, a repression was also detectable in
ROUTINE respiration and ETS capacity of intact cells. Moreover, ATP
levels were signiﬁcantly reduced in both model systems (Table 1).
Mitochondrial contentwas not changed byDEX treatment, as shown by
apreserved citrate synthase activity in the T-ALLmodel system,whereas
citrate synthase activity in 697/EU-3 cells was signiﬁcantly decreased
[9].We also investigated two GC-resistant cell lines, namely CCRF-CEM-
C7H2 R1C57 and R9C10. We did not detect any of the described
treatment related changes in the GC-resistant cell lines as observed in
GC-sensitive model systems (Table S1).
3.3. Gene expression of mitochondrial transporters
Analysis of the transcriptome after 24 h of treatment with DEX
revealed repression of important mitochondrial transport systems,
suggesting multiple changes in the mitochondrial membrane com-
position possibly involved in cell death.
3.3.1. Mitochondrial metabolite transporters
Based on gene expression array data, we found several mitochon-
drial transporters of the SLC25A family to be signiﬁcantly repressed
under DEX treatment in the ALL model systems CCRF-CEM-C7H2 and
697/EU-3, as well as in another childhood precursor B-ALL model
(NALM-6) (Table 2). The mitochondrial glutamate/H+ symporter
SLC25A22 (MIM 609302) and the dicarboxylate carrier SLC25A10
(MIM 606794), which transports dicarboxylates such as malate and
succinate across the mitochondrial membrane in exchange for
phosphate, sulfate, and thiosulfate, were among these genes. Further-
more, subunits E (ATP5I, MIM 601519) and C1 (ATP5G1, MIM 603192)
of the ATP synthase F0 complex F0 were downregulated.
Moreover, we analyzed gene expression data ([25] and Rainer et al.
in preparation) obtained for seven T-ALL patients and ten preB-ALL
patients with a hyperdiploid genotype for the above mentioned
mitochondrial transporters and the gene sets coding for ATP synthase
subunits (Table S2). ATP5G1 was repressed by 48%±13% in T-ALL
patients and 40%±15% in B-ALL patients. This supports the hypothesis
that GC-reduced energy metabolism may be an important event in
therapeutic cell death induction. The patient data concerning SLC25A10
Fig. 3. Downregulation of TIMM8A and TOMM40 protein expression in C7H2 cells after
24 h of DEX treatment. Representative Western blots of TIMM8A, TOMM40, and the
loading control COX IV (A), and a densitometric analysis of protein bands after imaging
by a Molecular Imager® VersaDoc™ MP 4000 system and subsequent integration by
Quantity One Software (B) are shown. Volumes of TIMM8A and TOMM40 protein
bands were normalized against the loading control and control values were set to 1.
(B) Arithmetic means±SEM and statistical signiﬁcance compared to controls
(**Pb0.01, ***Pb0.001) are shown. N=3.
Table 2
Downregulation of mitochondrial metabolite transporters and subunits of the ATP
synthase.
Gene name CEM-CCRF-C7H2 NALM-6 697/EU-3
MeanM Adj P MeanM Adj P MeanM Adj P
ATP5G1 −1.51 6.13E-05⁎ −0.52 5.58E-02 −0.80 1.41E-01
ATP5I −1.11 6.72E-03⁎ −0.11 7.66E-01 −0.25 7.86E-01
ODC1 −1.54 1.65E-10⁎ −0.56 1.25E-03⁎ −0.15 7.82E-01
SLC25A10 −1.55 7.37E-04⁎ −0.29 4.92E-01 −0.64 1.01E-02⁎
SLC25A15 −1.66 4.16E-06⁎ −0.62 9.44E-03⁎ −0.84 9.50E-04⁎
SLC25A19 −1.75 2.14E-07⁎ −0.58 8.76E-03⁎ −0.69 2.71E-02⁎
SLC25A22 −0.92 3.12E-02⁎ −0.49 4.90E-02⁎ −0.39 3.57E-01
Mean −1.43 −0.45 −0.54
Average log2 fold changes (meanM) and corresponding P-values adjusted by the
Benjamini–Hochberg method for the GC-sensitive cell lines CEM-CCRF-C7H2, NALM-6,
and 697/EU-3, representing extent and signiﬁcance of regulation after 24 h of treatment
with 100 nM dexamethasone. N=3.
⁎ Pb0.05.
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the cell lines. Nevertheless, either the glutamate or themalate/succinate
transporter was reduced in T-ALL and B-ALL patients (Table S2). Since
the transporter family SLC25A comprises very low abundant proteins,
even a small change could lead to a limitation inmitochondrial substrate
supply. Precursor B-ALL patientswithETV6/RUNX1 (previously referred
to as TEL/AML1) genotype [7], however, showed on average no change
in the expression of these genes (Table S2).
3.3.2. Mitochondrial protein translocases
Several mRNA encoding subunits of TIMM and TOMM, which are
responsible for uptake and insertion of mitochondrial proteins, were
signiﬁcantly repressed under DEX treatment (Table 3). We measured
gene expression levels in 3 different model systems of ALL, the CEM-
CCRF-C7H2, 697/EU-3, and the NALM-6 cell line, and found coordi-
nated downregulation, albeit to different extents, of mRNAs for 18
mitochondrial translocase subunits in all 3 cell lines (Table 3). In the
T-ALL model (CEM-CCRF-C7H2), 15 of the translocase subunit mRNAs
were signiﬁcantly downregulated (Benjamini–Hochberg adjusted
Pb0.05). In the precursor B-ALL models, most of the genes did not
reach statistical signiﬁcance; however, there was a trend of repression.Table 3
Downregulation of inner and outer mitochondrial membrane translocases and heat
shock protein 70 (HSPA9).
Gene name CEM-CCRF-C7H2 NALM6 697/EU-3
MeanM Adj P MeanM Adj P MeanM Adj P
HSPA9 -1.10 1.73E-08* -0.67 3.37E-03* -0.66 4.20E-02*
TIMM8A -0.95 1.28E-02* -0.13 4.64E-01 -0.26 4.90E-01
TIMM8B -0.15 9.19E-01 -0.78 6.67E-02 -0.44 8.47E-01
TIMM9 -1.22 3.12E-02* -0.74 1.56E-01 -0.72 4.84E-01
TIMM10 -0.91 7.60E-02 -0.37 1.76E-01 -0.62 1.34E-01
TIMM13 -1.93 5.72E-06* -0.44 7.95E-02 -0.70 9.35E-02
TIMM17A -1.07 8.71E-03* -0.62 5.19E-02 -0.54 4.18E-01
TIMM17B -0.82 4.54E-02* -0.23 3.92E-01 -0.25 6.09E-01
TIMM22 -0.68 8.57E-04* 0.09 7.06E-01 -0.40 1.47E-01
TIMM23 -0.66 1.13E-02* -0.35 1.99E-01 -0.58 1.20E-01
TIMM44 -1.50 4.16E-06* -0.63 1.95E-02* -0.91 2.89E-03*
TIMM50 -1.18 2.44E-07* -0.30 1.47E-01 -0.74 3.93E-03*
TOMM7 -1.44 8.74E-02 -0.06 8.91E-01 -0.22 9.19E-01
TOMM20 -0.95 4.59E-04* -0.42 1.78E-01 0.11 9.84E-01
TOMM22 -0.70 1.44E-02* -0.17 4.00E-01 -0.24 5.89E-01
TOMM34 -0.88 7.63E-04* -0.21 3.44E-01 -0.42 5.08E-02
TOMM40 -1.14 1.09E-05* -0.92 1.21E-01 -0.95 9.15E-02
TOMM40L -0.43 1.61E-02* -0.05 9.10E-01 -0.14 9.20E-01
TOMM70A -0.77 2.59E-03* -0.57 1.59E-02* -0.23 6.89E-01
mean -0.97 -0.40 -0.47
Average log2 fold changes (meanM) and corresponding P-values adjusted by the
Benjamini and Hochberg method for the GC-sensitive cell lines CEM-CCRF-C7H2,
NALM6, and 697/EU-3, representing extent and signiﬁcance of regulation after 24 h of
treatment with 100 nM dexamethasone. * Pb0.05. N=3.Heat shock protein 70 (HSPA9), amitochondrial chaperone essential for
the function of the TIM23 complex, was signiﬁcantly downregulated in
all tested cell lines. During transport of proteins by the TIM23 complex,
HSPA9 is recruited by TIMM44. Both geneswere repressed nearly to the
same extent in all cell lines tested, indicating that the function of TIM23
was strongly reduced. In order to verify our gene expression data, we
analyzed protein levels of TIMM8A and TOMM40, which were strongly
downregulated at the gene expression level. TIMM8Aand TOMM40 also
showeda42% and25%downregulation, respectively, at theprotein level
in DEX-treated cells (Fig. 3).
With regard to the TIM and TOM complexes, the ALL patients (T-ALL
and precursor B-ALL with hyperdiploidy) showed merely a slight
reductionof all analyzed TIMMandTOMMgenes andheat shockprotein
70 (Table S3). Nevertheless, TIMM8A and TIMM23 were among the 30
most negatively correlated genes with regard to GC bioactivity levels in
the serum of T-ALL patients (N=4); thus, high GC serum levels are
associated with low expression levels of these two genes and vice versa
(Rainer et al., in preparation).4. Discussion
Involvement of mitochondrial alterations and metabolic distur-
bances have been discussed as important events in GC-induced
apoptosis [9,11,26–28] but not studied in detail. Mitochondrial
membrane alterations as shown in the present studymight contribute
to the collapse of vital metabolic pathways,making cells susceptible to
apoptosis.
724 K. Eberhart et al. / Biochimica et Biophysica Acta 1807 (2011) 719–725After 24 h of DEX treatment, the observed repression of respiration
upon cell membrane permeabilization with digitonin in both GC-
sensitivemodel systems and the detected cytochrome c release in T-ALL
cells suggest changes in mitochondrial membrane properties that
contribute to apoptosis, possibly via induction of permeability transition.
Digitonin exerts its effect by interaction with cholesterol. The
cholesterol content is much lower in mitochondrial compared to
plasma membranes; therefore, digitonin concentrations used for
plasma membrane permeabilization usually do not affect mitochon-
drial membranes. A direct effect of digitonin on the mitochondrial
membrane cannot be excluded, but it appears unlikely for two
reasons: (i) we used a digitonin concentration for plasma membrane
permeabilization that was much lower than required for mitochon-
drial outer membrane permeabilization (we also checked lower
concentrations for GC-treated cell, but the effect was the same), and
(ii) mitochondrial cholesterol content was not elevated, which would
have increased the sensitivity to digitonin (data not shown).
We hypothesize that DEX treatment alters mitochondrial mem-
brane composition, as shown by reduced protein content of two
translocases and the strong downregulation of numerous transporters
on mRNA level and thus alters mitochondrial membrane properties,
making mitochondria more fragile and sensitive to the onset of
apoptosis. The importance of the observed phenomena is supported
by the fact that none of the GC-resistant ALL model systems tested
showed any of these changes. The decreased mitochondrial activity in
intact cells after 36 h suggests an accumulation of injuries over time.
Changed mitochondrial membrane properties, damage of the respi-
ratory complexes, and/or reduced substrate import could explain the
repressed mitochondrial respiratory activity and ATP levels after 36 h
of DEX treatment.
Our gene expression data revealed a downregulation of metabolite
transporters at themRNA level. A disturbed substrate transport results in
substrate depletion and impairmentof differentmetabolic pathways, e.g.
amino acid metabolism, the urea cycle, and mitochondrial respiration
[1,29]. Recent data show a strong correlation between disturbed
mitochondrial metabolite transport and disease [30]. Disturbed gluta-
mate uptake by its main transporter SLC25A22 results in impairment of
the malate/aspartate shuttle and a malfunction of the urea cycle,
resulting in reduced nitrogen detoxiﬁcation. Malate, a metabolite
produced in the mitochondrial matrix as well as in the cytoplasm, is
taken up by the mitochondria via the dicarboxylate transporter
(SLC25A10), which was found to be repressed by DEX treatment.
Moreover, we found the mitochondrial C5–C7 oxodicarboxylate
carrier SLC25A21 repressed in all cell lines and in 70% of all investigated
ALL patients. In addition to the regulation of metabolite transporters,
TIMMs and TOMMs were downregulated both at the gene and the
protein levels. Except TIMM21, all translocases of the inner mitochon-
drial membrane are essential for cell viability [31]. A reduction in TIMM
and TOMM proteins results in repressed transport and insertion of
newly synthesized proteins into mitochondria, which might potentiate
the described transcriptional downregulations of the metabolite
transporters and the ATP synthase. ATP levels are crucial for cell
viability and a reduction is a strong cell death trigger [32]. We reported
previously [9] that a moderate reduction in ATP levels by a non-toxic
dose of 2-deoxyglucose sensitized cells dramatically to GC. This effect of
2-deoxyglucose on GC-induced cell death could be reverted by the
addition of pyruvate and a concomitant increase in ATP in the B-ALL
model. In the T-ALL model, pyruvate addition did not result in an
increase in ATP levels and the effect of 2-DG on apoptosis could not be
reverted.
Patient data revealed strong differences between the response of
T- and precursor B-ALL cells to GC treatment and gene expression
proﬁles among ALL patients also showed great variability. Individual
patients showed signiﬁcant regulations in many of the described
genes, others no regulation at all, underscoring the need for
personalized medical treatment of children suffering from ALL.The mechanism of GC-induced apoptosis and the phenomenon of
GC resistance are still under investigation. In summary, our data
provide evidence that alterations in mitochondrial membrane and
catalytic properties are an early event in GC-induced metabolic
disturbances leading to apoptosis. In contrast, in GC-resistant cells, all
tested mitochondrial respiratory parameters remain unchanged,
suggesting that a preserved mitochondrial function and membrane
properties protect resistant cells against GC-induced metabolic stress.
Further support for this hypothesis comes from the transcriptional
proﬁling of GC-resistant T-ALL cell lines, which demonstrated the
activation of bioenergetic pathways required for proliferation [11].
This increase may suppress the apoptotic potential and offset the
metabolic crisis initiated by GC signaling. In combination with the
observations that selective metabolic inhibitors such as 2-deoxyglu-
cose could revert resistance in vitro and ex vivo in GC-resistant
leukemic cells [26] and potentiated the GC effect in GC-sensitive
leukemia cells [9], further studies on the role of cellular metabolism
and its therapeutic modulation in GC-triggered apoptosis of lympho-
blastic leukemia cells are warranted.
Acknowledgments
This studywas funded by BayGene, the Austrian FederalMinistry for
Education, Science, and Culture (GENAU-CH.I.L.D.), and ONCOTYROL, a
COMET Center funded by the Austrian Research Promotion Agency
(FFG), the Tiroler Zukunftsstiftung, and the Styrian Business Promotion
Agency (SFG). The Tyrolean Cancer Research Institute is supported by
the “Tiroler Landeskrankenanstalten GmbH (TILAK),” the “Tyrolean
Cancer Aid Society,” various businesses, ﬁnancial institutions, and the
people of Tyrol. We also thank Prof. Frederic Bouillaud for fruitful
discussions, and Bastian Oppl, for providing unpublished GC bioassay
data.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
doi:10.1016/j.bbabio.2010.12.010.
References
[1] F. Palmieri, The mitochondrial transporter family (SLC25): physiological and
pathological implications, Pﬂügers Arch. Eur. J. Physiol. 447 (2004) 689–709.
[2] E.R. Kunji, The role and structure of mitochondrial carriers, FEBS Lett. 564 (2004)
239–244.
[3] S. Sugiyama, S. Moritoh, Y. Furukawa, T. Mizuno, Y.M. Lim, L. Tsuda, Y. Nishida,
Involvement of the mitochondrial protein translocator component Tim50 in
growth, cell proliferation and the modulation of respiration in drosophila,
Genetics 176 (2007) 927–936.
[4] N. Joza, S.A. Susin, E. Daugas, W.L. Stanford, S.K. Cho, C.Y. Li, T. Sasaki, A.J. Elia, H.Y.
Cheng, L. Ravagnan, K.F. Ferri, N. Zamzami, A.Wakeham, R. Hakem, H. Yoshida, Y.Y.
Kong, T.W. Mak, J.C. Zuniga-Pﬂucker, G. Kroemer, J.M. Penninger, Essential role of
the mitochondrial apoptosis-inducing factor in programmed cell death, Nature
410 (2001) 549–554.
[5] L. Scorrano, S.J. Korsmeyer, Mechanisms of cytochrome c release by proapoptotic
BCL-2 family members, Biochem. Biophys. Res. Commun. 304 (2003) 437–444.
[6] M. Dordelmann, A. Reiter, A. Borkhardt, W.D. Ludwig, N. Gotz, S. Viehmann, H.
Gadner, H. Riehm, M. Schrappe, Prednisone response is the strongest predictor of
treatment outcome in infant acute lymphoblastic leukemia, Blood 94 (1999)
1209–1217.
[7] C.H. Pui, W.E. Evans, Treatment of acute lymphoblastic leukemia, N. Engl. J. Med.
354 (2006) 166–178.
[8] R. Koﬂer, The molecular basis of glucocorticoid-induced apoptosis of lympho-
blastic leukemia cells, Histochem. Cell Biol. 114 (2000) 1–7.
[9] K. Eberhart, K. Renner, I. Ritter, M. Kastenberger, K. Singer, C. Hellerbrand, M.
Kreutz, R. Koﬂer, P.J. Oefner, Low doses of 2-deoxy-glucose sensitize acute
lymphoblastic leukemia cells to glucocorticoid-induced apoptosis, Leukemia 23
(2009) 2167–2170.
[10] M.E. Tome, D.B. Johnson, B.K. Samulitis, R.T. Dorr, M.M. Briehl, Glucose 6-phosphate
dehydrogenaseoverexpressionmodels glucose deprivationand sensitizes lymphoma
cells to apoptosis, Antioxid. Redox Signal. 8 (2006) 1315–1327.
[11] A.H. Beesley, M.J. Firth, J. Ford, R.E. Weller, J.R. Freitas, K.U. Perera, U.R. Kees,
Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated
with a proliferative metabolism, Br. J. Cancer 100 (2009) 1926–1936.
725K. Eberhart et al. / Biochimica et Biophysica Acta 1807 (2011) 719–725[12] E.M. Strasser-Wozak, R. Hattmannstorfer, M. Hala, B.L. Hartmann, M. Fiegl, S.
Geley, R. Koﬂer, Splice site mutation in the glucocorticoid receptor gene causes
resistance to glucocorticoid-induced apoptosis in a human acute leukemic cell
line, Cancer Res. 55 (1995) 348–353.
[13] H.W. Findley Jr., M.D. Cooper, T.H. Kim, C. Alvarado, A.H. Ragab, Two new acute
lymphoblastic leukemia cell lines with early B-cell phenotypes, Blood 60 (1982)
1305–1309.
[14] S. Schmidt, J.A. Irving, L. Minto, E. Matheson, L. Nicholson, A. Ploner, W. Parson, A.
Koﬂer, M. Amort, M. Erdel, A. Hall, R. Koﬂer, Glucocorticoid resistance in two key
models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid
receptor, FASEB J. 20 (2006) 2600–2602.
[15] M. Zhou, L. Gu, F. Li, Y. Zhu, W.G. Woods, H.W. Findley, DNA damage induces
a novel p53-survivin signaling pathway regulating cell cycle and apoptosis
in acute lymphoblastic leukemia cells, J. Pharmacol. Exp. Ther. 303 (2002)
124–131.
[16] I. Nicoletti, G. Migliorati, M.C. Pagliacci, F. Grignani, C. Riccardi, A rapid and simple
method for measuring thymocyte apoptosis by propidium iodide staining and
ﬂow cytometry, J. Immunol. Meth. 139 (1991) 271–279.
[17] S. Stadlmann, K. Renner, J. Pollheimer, P.L. Moser, A.G. Zeimet, F.A. Offner, E.
Gnaiger, Preserved coupling of oxidative phosphorylation but decreased
mitochondrial respiratory capacity in IL-1beta-treated human peritoneal meso-
thelial cells, Cell Biochem. Biophys. 44 (2006) 179–186.
[18] E. Gnaiger, Capacity of oxidative phosphorylation in human skeletal muscle: new
perspectives of mitochondrial physiology, Int. J. Biochem. Cell Biol. 41 (2009)
1837–1845.
[19] A.V. Kuznetsov, S. Schneeberger, R. Seiler, G. Brandacher, W. Mark, W. Steurer, V.
Saks, Y. Usson, R. Margreiter, E. Gnaiger, Mitochondrial defects and heterogeneous
cytochrome c release after cardiac cold ischemia and reperfusion, Am. J. Physiol.
Heart Circ. Physiol. 286 (2004) H1633–H1641.
[20] D. Pesta, E. Gnaiger, High-resolution respirometry. OXPHOS protocols for human
cell cultures and permeabilized ﬁbres from small biopsies of human muscle, in: C.
Palmeira, A. Moreno (Eds.), Mitochondrial Bioenergetics: Methods and Protocols,
2010.
[21] J. Rainer, C. Ploner, S. Jesacher, A. Ploner, M. Eduardoff, M. Mansha, M. Wasim, R.
Panzer-Grumayer, Z. Trajanoski, H. Niederegger, R. Koﬂer, Glucocorticoid-regulatedmicroRNAs and mirtrons in acute lymphoblastic leukemia, Leukemia 23 (2009)
746–752.
[22] Z. Wu, R.A. Irizarry, R. Gentleman, F. Martinez-Murillo, F. Spencer, A model-based
background adjustment for oligonucleotide expression arrays, J. Am. Stat. Assoc.
99 (2004) 909–918.
[23] G. Smyth, Linear models and empirical Bayes methods for assessing differential
expression in microarray experiments, Stat. Appl. Genet. Mol. Biol. 3 (2004) 29.
[24] Y. Benjamini, Y. Hochberg, Controlling the false discovery rate: a practical and
powerful approach to multiple testing, J. R. Statist. Soc. B 57 (1995) 289–300.
[25] S. Schmidt, J. Rainer, S. Riml, C. Ploner, S. Jesacher, C. Achmuller, E. Presul, S.
Skvortsov, R. Crazzolara, M. Fiegl, T. Raivio, O.A. Janne, S. Geley, B. Meister, R.
Koﬂer, Identiﬁcation of glucocorticoid-response genes in children with acute
lymphoblastic leukemia, Blood 107 (2006) 2061–2069.
[26] E. Hulleman, K.M. Kazemier, A. Holleman, D.J. VanderWeele, C.M. Rudin, M.J.
Broekhuis, W.E. Evans, R. Pieters, M.L. den Boer, Inhibition of glycolysis modulates
prednisolone resistance in acute lymphoblastic leukemia cells, Blood 113 (2009)
2014–2021.
[27] M.E. Tome, N.W. Lutz, M.M. Briehl, Overexpression of catalase or Bcl-2 delays or
prevents alterations in phospholipid metabolism during glucocorticoid-induced
apoptosis in WEHI7.2 cells, Biochim. Biophys. Acta 1642 (2003) 149–162.
[28] M.E. Tome, N.W. Lutz, M.M. Briehl, Overexpression of catalase or Bcl-2 alters
glucose and energy metabolism concomitant with dexamethasone resistance,
Biochim. Biophys. Acta 1693 (2004) 57–72.
[29] M.J. Lindhurst, G. Fiermonte, S. Song, E. Struys, F. De Leonardis, P.L. Schwartzberg,
A. Chen, A. Castegna, N. Verhoeven, C.K. Mathews, F. Palmieri, L.G. Biesecker,
Knockout of Slc25a19 causes mitochondrial thiamine pyrophosphate depletion,
embryonic lethality, CNSmalformations, and anemia, Proc. Natl Acad. Sci. USA 103
(2006) 15927–15932.
[30] F. Palmieri, Diseases caused by defects of mitochondrial carriers: a review,
Biochim. Biophys. Acta 1777 (2008) 564–578.
[31] D. Mokranjac, W. Neupert, Protein import into mitochondria, Biochem. Soc. Trans.
33 (2005) 1019–1023.
[32] J.M. Garland, A. Halestrap, Energy metabolism during apoptosis. Bcl-2 promotes
survival in hematopoietic cells induced to apoptose by growth factor withdrawal
by stabilizing a form of metabolic arrest, J Biol. Chem. 272 (1997) 4680–4688.
